Perjeta
AstraZeneca diabetes drug approved for use in Scotland
November 11, 2014Sales and Marketing Afinitor, AstraZeneca, Eylea, Onglyza, Perjeta, SMC, diabetes, type 2
The Scottish Medicines Consortium (SMC) has shown AstraZeneca’s Onglyza (saxagliptin) the green light to be used with insulin in patients …
New cancer drugs escalate Roche earnings
October 16, 2014Research and Development, Sales and Marketing Cancer, Herceptin (trastuzumab), Kadcyla, Perjeta, Q3, Roche, ado-trastuzumab emtansine, pertuzumab
Roche’s sales saw solid growth in the first nine months of the year, increased by the firm’s new cancer medicines. …
Roche’s Perjeta sees ‘impressive’ survival rates
September 29, 2014Sales and Marketing Cancer, ESMO, Perjeta, Roche, breast, madrid
Roche’s oncology drug Perjeta combined with other medicines can help certain breast cancer patients live longer. This is according to …
Herceptin faces UK competition within months
April 11, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biocon, Herceptin, Hospira, Perjeta, breast cancer
Roche’s blockbuster breast cancer drug Herceptin may soon be under threat from copycat treatments after a court in the UK …
Oncology drives Roche profits
January 30, 2014Sales and Marketing Actemra, Perjeta, Roche, Swiss, q4
Sales at Roche’s pharma division rose 7% year-on-year in 2013, driven largely by strong performances from its oncology portfolio. Group …
Perjeta becomes first approved drug for early breast cancer
October 1, 2013Sales and Marketing FDA, Herceptin, Perjeta, Roche
Roche’s Perjeta has become the first preoperative breast cancer drug to be authorised by the FDA after it was granted …
Roche breast cancer drug Perjeta rejected by NICE
August 6, 2013Sales and Marketing Cancer, NICE, Perjeta, Roche
NICE is not recommending Roche’s next generation breast cancer drug Perjeta as a treatment for a particular type of advanced …
FDA gives Perjeta priority
July 3, 2013Sales and Marketing FDA, Perjeta, Roche, breast cancer
The FDA has granted priority review status to an application for Roche’s Perjeta to be used before surgery in HER2-positive …
Perjeta approved in EU
March 7, 2013Sales and Marketing Perjeta, Roche
Roche’s oncology brand Perjeta has been approved in Europe to treat patients with an aggressive form of breast cancer. The …
Perjeta recommended in EU
December 18, 2012Sales and Marketing CHMP, Cancer, Perjeta, Roche
Roche’s breast cancer treatment Perjeta has been given the thumbs up by the CHMP, paving the way for its approval …
Perjeta reduces risk of death
December 11, 2012Sales and Marketing Cancer, Perjeta, Roche
Roche’s cancer drug Perjeta helps reduce the risk of death by 34% in patients with HER2-positive metastatic breast cancer (mBC), …
Roche winning on Perjeta supply, but running short of Boniva
August 20, 2012Manufacturing and Production, Sales and Marketing Boniva, Perjeta, Roche, breast cancer
Roche is getting production for its new breast cancer drug Perjeta back on track after some initial teething troubles, but …
Roche posts strong sales results
July 27, 2012Sales and Marketing Pegasys, Perjeta, Roche, Zelboraf, dalcetrapib
Roche has published healthy revenue growth for the first half of 2012, but its profits have taken a hit. The …
Roche’s Perjeta increases survival
June 27, 2012Research and Development, Sales and Marketing EMA, FDA, Herceptin, Perjeta, Roche, breast cancer
Roche’s new drug Perjeta has scored another trial success by increasing overall survival in certain breast cancer patients. The new …
FDA approves Roche’s breast cancer drug
June 11, 2012Sales and Marketing EMA, FDA, Perjeta, Roche, breast cancer
US regulators have approved Roche’s new breast cancer drug after granting it a priority review to speed up the process. …
